- Maud Brandely, MD, PhD joins as Chief Medical Officer
- John Felitti, JD, LLM joins as General Counsel & Corporate Secretary
Strasbourg, France, March 17, 2016 – Transgene SA (Euronext: TNG) today announced the appointment of two new executives to its leadership team.
Maud Brandely, MD, PhD joins Transgene from Pierre Fabre Oncologie, where she most recently served as Director of Clinical Development. John Felitti, JD, LLM joins from Sanofi, where he was Associate Vice President, Corporate Law, Finance and Securities Law. Both bring many years of industry and leadership experience to their positions.
Philippe Archinard, PhD, Chairman and Chief Executive Officer of Transgene, said: “I am delighted to welcome Maud and John to Transgene. Maud brings extensive oncology clinical and regulatory experience, with a solid track record of successfully bringing drugs through clinical development to marketing approval. John’s transatlantic experience as both an external legal advisor and in-house counsel will provide us invaluable expertise as we expand our collaboration activities on both sides of the Atlantic.”
Dr. Brandely and Mr. Felitti will be members of Transgene’s Executive Committee and both will report to Mr. Archinard.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.67 (c)||-1.11%||43 250|